U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3F8
Molecular Weight 188.0193
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERFLUTREN

SMILES

FC(F)(F)C(F)(F)C(F)(F)F

InChI

InChIKey=QYSGYZVSCZSLHT-UHFFFAOYSA-N
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11

HIDE SMILES / InChI

Molecular Formula C3F8
Molecular Weight 188.0193
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Perflutren is a diagnostic drug that is used for the contrast enhancement during echocardiographic. It consists of lipid-coated microspheres filled with octafluoropropane gas. Ultrasound waves make the microspheres resonate and reflect a strong signal to an ultrasound machine. This results in a difference of density between gas-filled bubbles and blood around them and improves contrast of resulting images. Perflutren is used in patients with suboptimal echocardiograms to opacify the left ventricular chamber and improve the delineation of the heart borders.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
DEFINITY

Approved Use

DEFINITY is an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

Launch Date

2001
Doses

Doses

DosePopulationAdverse events​
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Disc. AE: Urticaria, Pruritus...
AEs leading to
discontinuation/dose reduction:
Urticaria
Pruritus
Dizziness
Chest pain
Dyspnea
Back pain
Sources: Page: p.6
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1
Disc. AE: Anaphylactoid reaction...
AEs leading to
discontinuation/dose reduction:
Anaphylactoid reaction (serious)
Sources: Page: p.1
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Disc. AE: Cardiac arrest, Respiratory arrest...
AEs leading to
discontinuation/dose reduction:
Cardiac arrest (grade 5)
Respiratory arrest (grade 5)
Shock (serious)
Syncope (serious)
Arrhythmia (serious)
Hypertension (serious)
Hypotension (serious)
Dyspnea (serious)
Hypoxia (serious)
Chest pain (serious)
Respiratory distress (serious)
Stridor (serious)
Wheezing (serious)
Loss of consciousness (serious)
Convulsions (serious)
Sources: Page: p.1, 5
AEs

AEs

AESignificanceDosePopulation
Back pain Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Chest pain Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Dizziness Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Dyspnea Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Pruritus Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Urticaria Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.6
unhealthy, 18 - 93
n = 1716
Health Status: unhealthy
Condition: Coronary artery disease
Age Group: 18 - 93
Sex: M+F
Population Size: 1716
Sources: Page: p.6
Anaphylactoid reaction serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1
Cardiac arrest grade 5
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Respiratory arrest grade 5
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Arrhythmia serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Chest pain serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Convulsions serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Dyspnea serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Hypertension serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Hypotension serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Hypoxia serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Loss of consciousness serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Respiratory distress serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Shock serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Stridor serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Syncope serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Wheezing serious
Disc. AE
10 uL/kg 1 times / 30 min multiple, intravenous
Recommended
Dose: 10 uL/kg, 1 times / 30 min
Route: intravenous
Route: multiple
Dose: 10 uL/kg, 1 times / 30 min
Sources: Page: p.1, 5
unhealthy
Health Status: unhealthy
Condition: Coronary artery disease
Sources: Page: p.1, 5
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Chromatic contrast thresholds as a prognostic test for visual improvement after macular hole surgery: color vision and macular hole surgery outcome.
2001
Retinal detachment after pneumatic displacement for subfoveal hemorrhage.
2001
Prostate cancer: contrast-enhanced us for detection.
2001 Apr
Recurrences of retinal detachment after vitreoretinal surgery, and surgical approach.
2001 Apr-Jun
Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement.
2001 Jan
Definity Health shifts risk all the way to the patient; employers attracted to 'new consumerism'.
2001 Jul
Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
2001 May-Jun
[Vitreoretinal surgery with intraocular C3F8 tamponade for retinal detachment due to macular hole without face-down positioning].
2001 Nov
The impact of emission power on the destruction of echo contrast agents and on the origin of tissue harmonic signals using power pulse-inversion imaging.
2001 Nov
Directed biopsy during contrast-enhanced sonography of the prostate.
2002 Apr
Management of glaucoma after retinal detachment surgery.
2002 Apr
Bioeffects of myocardial contrast microbubble destruction by echocardiography.
2002 Aug
Effects of Optison on pulmonary gas exchange and hemodynamics.
2002 Aug
Vitreous surgery in highly myopic retinal detachment resulting from a macular hole.
2002 Aug
Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model.
2002 Dec
Contrast enhanced duplex ultrasound imaging of the mesenteric arteries.
2002 Jan
Shortening the duration of prone positioning after macular hole surgery- comparison between 1-week and 1-day prone positioning.
2002 Jan-Feb
Visualization of uveal perfusion by contrast-enhanced harmonic ultrasonography at a low mechanical index: a pilot animal study.
2002 Mar
Seeking consensus: contrast ultrasound in radiology.
2002 Mar
A cost-utility analysis of interventions for severe proliferative vitreoretinopathy.
2002 Mar
Contrast material-enhanced abdominal US examinations with DMP 115 (DEFINITY) provides additional diagnostic information with potential for changes in patient management.
2002 May
Microvascular rheology of Definity microbubbles after intra-arterial and intravenous administration.
2002 May
Angle closure glaucoma following pupillary block in an aphakic perfluoropropane gas-filled eye.
2002 Sep
Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome.
2002 Sep
Nitrous oxide anaesthesia in the presence of intraocular gas can cause irreversible blindness.
2002 Sep 7
Lower receiving frequencies than transmitting frequencies could yield improved results for contrast imaging: an in vivo study in closed chest canines.
2003 Apr
Inverted pneumatic retinopexy.
2003 Nov
Early macular holes with retinoschisis in highly myopic eyes.
2003 Oct
Comparison of scleral buckling with combined scleral buckling and pars plana vitrectomy in the management of rhegmatogenous retinal detachment with unseen retinal breaks.
2003 Oct
Better success of retinal reattachment with long-standing gas tamponade in highly myopic eyes.
2003 Oct
Extra-low acoustic power harmonic images of the liver with perflutren: novel imaging for real-time observation of liver perfusion.
2003 Sep
Comparison of intravenous myocardial contrast echocardiography and low-dose dobutamine echocardiography for predicting left ventricular functional recovery following acute myocardial infarction.
2003 Sep 1
Real-time assessment of myocardial perfusion during balloon angioplasty of the left anterior descending coronary artery.
2003 Sep 15
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:37 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:37 GMT 2023
Record UNII
CK0N3WH0SR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PERFLUTREN
EMA EPAR   II   INN   JAN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LUMINITY
Brand Name English
DMP115
Code English
OCTAFLUORO-PROPANE
Systematic Name English
PERFLUTREN [EMA EPAR]
Common Name English
PERFLUOROPROPANE
MI  
Systematic Name English
PERFLUTREN [VANDF]
Common Name English
Octafluoropropane
VANDF  
Systematic Name English
OCTAFLUOROPROPANE [VANDF]
Common Name English
PERFLUOROPROPANE [MI]
Common Name English
1,1,1,2,2,3,3,3-OCTAFLUOROPROPANE
Systematic Name English
OPTISON
Brand Name English
FS069
Code English
OXTAFLUOROPROPANE [VANDF]
Common Name English
PERFLUTREN [ORANGE BOOK]
Common Name English
PROPANE, OCTAFLUORO-
Systematic Name English
DMP-115
Code English
perflutren [INN]
Common Name English
Perflutren [WHO-DD]
Common Name English
PERFLUTREN [USAN]
Common Name English
FS-069
Code English
PERFLUTREN [MART.]
Common Name English
MRX-115
Code English
DEFINITY
Brand Name English
PERFLUTREN [II]
Common Name English
PERFLUOROPROPANE [INCI]
Common Name English
PERFLUTREN [JAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS LUMINITY (AUTHORIZED: ECHOCARDIOGRAPHY)
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
NDF-RT N0000175864
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
EMA ASSESSMENT REPORTS OPTISON (AUTHORIZED: ECHOCARDIOGRAPHY)
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
NCI_THESAURUS C1937
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
NDF-RT N0000010259
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C47664
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
LACTMED
Perflutren
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
SMS_ID
100000090070
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
CHEBI
31980
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
MESH
C418027
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
INN
7932
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
HSDB
8074
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
WIKIPEDIA
OCTAFLUOROPROPANE
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
RXCUI
283753
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY RxNorm
DAILYMED
CK0N3WH0SR
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL1663
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
FDA UNII
CK0N3WH0SR
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
PUBCHEM
6432
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
MESH
C042852
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
DRUG CENTRAL
2104
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
CAS
76-19-7
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-941-9
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
DRUG BANK
DB00556
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
EVMPD
SUB20657
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
MERCK INDEX
m8543
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID9052503
Created by admin on Fri Dec 15 16:35:38 GMT 2023 , Edited by admin on Fri Dec 15 16:35:38 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY